Despite improvements in disease management, multiple myeloma (MM) remains incurable.
Conventional treatment methods are unsatisfactory, leading to a pattern of regression and …

Advances in the treatment of multiple myeloma have resulted in dramatic improvements in
outcomes for patients. The newly emerging profiling of mutations emerging as a …

Simple Summary The bone marrow (BM) microenvironment plays a crucial role in
pathogenesis of multiple myeloma (MM), and delineation of the intracellular signaling …

Multiple myeloma remains an incurable plasma cell neoplasm. New insights into its
pathogenesis have identified signaling pathways that have become potential therapeutic …

Multiple myeloma (MM) is characterized by excess monoclonal plasma cells in the bone
marrow (BM), in most cases associated with monoclonal protein in blood or urine. Nearly 50 …

Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of
clonal plasma cells in the bone marrow (BM). It is known that early genetic mutations in post …

Abstract The Ras/Raf/MEK/extracellular signal regulated kinase (ERK)(Ras/mitogen-
activated protein kinases (MAPK)) signal transduction pathway is a crucial mediator of many …

Multiple myeloma (MM) is a clonal plasma cell malignancy that develops primarily in the
bone marrow (BM), where reciprocal interactions with the BM niche foster MM cell survival …

Multiple myeloma (MM) is an incurable disease characterized by the proliferation of end-
stage B lymphocytes (plasma cells, PCs). As a consequence of myeloma growth in the bone …

Direct therapeutic targeting of oncogenic RAS is currently still impossible due to lack of
suitable pharmacological inhibitors. Because specific blockade of druggable RAS effectors …